Further progress in CLL therapy

Blood

Volumn 112, Issue 4, 2008, Pages 924-925

  Montserrat, Emili ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; FLUDARABINE; MITOXANTRONE; RITUXIMAB;

CANCER CHEMOTHERAPY; CANCER SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; GOLD STANDARD; HUMAN; NOTE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS;

EID: 59149098347     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2008-05-155721     Document Type: Note

References (2)

1. Rawstron AC, Villamor N, Ritgen M, et al. International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia. Leukemia. 2007;21:956-964.
2. Montserrat E. CLL therapy: achieving minimal residual disease negative status as a goal. J Clin Oncol. 2005;23:2884-2885.